NCT03655522View on ClinicalTrials.gov

NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 14, 2015

Primary Completion Date

September 2, 2015

Study Completion Date

September 2, 2015

Conditions
Safety
Interventions
DRUG

NAVX-010

Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.

DRUG

Placebo

There were two Placebos per group.

Sponsors

Lead Sponsor

Algenis SpA

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

Algenis SpA

INDUSTRY